Physician profile
Daniel Condit
NPI 1114306693
$562.18
in general payments reported to CMS, 2019-2025
8 companies · $209 in 2025
The $209 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $39.15 · 2023: $23.12 · 2024: $291 · 2025: $209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $500 · Education: $23.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $499.91 |
| Education | $23.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pulmonx Corporation | $146.09 | 2024 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Intuitive Surgical, INC. | $141.57 | 2025 | |
| Pinnacle Biologics, INC | $110.08 | 2024-2025 | Photofrin |
| Abiomed | $39.65 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $39.15 | 2022 | |
| Alcresta Therapeutics, INC. | $36.76 | 2024 | Relizorb |
| Abbott Laboratories | $25.76 | 2024 | 2nd Gen Centrimag Primary Console |
| Astrazeneca Pharmaceuticals Lp | $23.12 | 2023 | Breztri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Condit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.